Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTK | P33981 | 20/20 | 0.86 |
| ▸ | AURKA | O14965 | 9/20 | 0.86 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.63 |
| ▸ | CDK2 | P24941 | 2/20 | 0.63 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.63 |
| ▸ | PLK1 | P53350 | 3/20 | 0.61 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.58 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.58 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.58 |
| ▸ | MELK | Q14680 | 1/20 | 0.58 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.58 |
| ▸ | NEK6 | Q9HC98 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1559172 | 0.93 | TTK (1.00) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1559663 | 0.93 | TTK (1.00) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1559656 | 0.85 | TTK (0.71) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1560168 | 0.84 | TTK (0.73) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1896096 | 0.84 | TTK (0.84) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1889499 | 0.84 | TTK (0.86) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1560138 | 0.83 | TTK (0.82) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL526629 | 0.83 | TTK (0.80) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL526154 | 0.83 | TTK (0.80) | TTKAURKACCNA2CDK2CCNA1 | |
| SCHEMBL1560061 | 0.80 | TTK (0.69) | TTKAURKACCNA2CDK2CCNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2303891-B1 | PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS | SERVIER LAB (FR) | 2016-02-17 | — | — | EP | claimed |
| US-8846701-B2 | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-09-30 | — | — | US | claimed |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | US | claimed |
| EP-2303891-B1 | PYRAZOLO-QUINAZOLINES AS PROTEIN KINASE ACTIVITY MODULATORS | SERVIER LAB (FR) | 2016-02-17 | — | — | EP | disclosed |
| US-8846701-B2 | Pyrazolo-quinazolines | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2014-09-30 | — | — | US | disclosed |
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105542-A1 | PYRAZOLO--QUINAZOLINES | PDXK, MAP4K5, MAP3K1 | TTK 8/4885AURKA 370/4885CCNA2 690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.